Takeda Pharmaceutical
Takeda Pharmaceutical Company Ltd is a Japanese biopharmaceutical company focused on the research, development, and commercialization of prescription medicines. The enterprise structures its business operations around five core therapeutic areas: gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Primary revenue drivers include proprietary prescription drugs such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and plasma products. Takeda occupies a leading position as the largest pharmaceutical enterprise in Asia and ranks among the top global drug makers by revenue. Its principal end markets comprise healthcare providers, hospitals, and retail pharmacies across North America, Europe, Japan, and emerging markets. The company is headquartered in Tokyo, Japan, and maintains primary listings on the Tokyo Stock Exchange and New York Stock Exchange.
54 of the funds FundTelligence covers report a position in Takeda Pharmaceutical.
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 54
Funds holding Takeda Pharmaceutical
- DWS Invest CROCI Japan — DWS · 3.3 % (full portfolio disclosed, June 2026)
- Danske Invest Japan Index Restricted — Danske Invest · 2.35 % (full portfolio disclosed, July 2026)
- Invesco Net Zero Global Investment Grade Corporate Bond Fund — Invesco · 2.1 % (largest positions only, April 2026)
- DWS Invest CROCI Global Dividends — DWS · 1.92 % (full portfolio disclosed, June 2026)
- Storebrand Japan — Storebrand · 1.77 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 1.17 % (full portfolio disclosed, October 2026)
- Lannebo Marknad Japan — Lannebo · 1.15 % (full portfolio disclosed, June 2026)
- Nordea Japanese Sustainable Enhanced — Nordea Funds · 1.14 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 54 funds holding it.